CTOs on the Move

HTG Molecular Diagnostics

www.htgmolecular.com

 
Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

HTG Molecular Diagnostics raised $22.5M on 10/03/2019

Similar Companies

R I Analytical Laboratories Inc

R I Analytical Laboratories Inc is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.

Cerecor

Cerecor is building a global biopharmaceutical enterprise with a near-term pipeline of six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first-in-class compounds.

Percivia

Percivia is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.